BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37240197)

  • 1. Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.
    Plano F; Gigliotta E; Corsale AM; Azgomi MS; Santonocito C; Ingrascì M; Di Carlo L; Augello AE; Speciale M; Vullo C; Rotolo C; Camarda GM; Caccamo N; Meraviglia S; Dieli F; Siragusa S; Botta C
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240197
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
    Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
    Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
    Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
    Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
    J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the Microenvironment for Treating Multiple Myeloma.
    Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
    Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
    Front Immunol; 2020; 11():613007. PubMed ID: 33488620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.
    Iannozzi NT; Marchica V; Toscani D; Burroughs Garcìa J; Giuliani N; Storti P
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.
    Plano F; Corsale AM; Gigliotta E; Camarda G; Vullo C; Di Simone M; Shekarkar Azgomi M; Speciale M; Carlisi M; Caccamo N; Dieli F; Meraviglia S; Siragusa S; Botta C
    Hematol Rep; 2023 Jan; 15(1):23-49. PubMed ID: 36648882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep Learning Enables Spatial Mapping of the Mosaic Microenvironment of Myeloma Bone Marrow Trephine Biopsies.
    Hagos YB; Lecat CSY; Patel D; Mikolajczak A; Castillo SP; Lyon EJ; Foster K; Tran TA; Lee LSH; Rodriguez-Justo M; Yong KL; Yuan Y
    Cancer Res; 2024 Feb; 84(3):493-508. PubMed ID: 37963212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B; Edwards CM
    Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of multiple myeloma].
    Rasche L; Weinhold N
    Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
    Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L
    Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.